Evidence map›Paper›PMID 33799933›Full record

ArticleJournal of clinical medicine2021

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis.

Aneta Szudy-Szczyrek, Oliwia Bachanek-Mitura, Tomasz Gromek, Karolina Chromik, Andrzej Mital, Michał Szczyrek, Witold Krupski, Justyna Szumiło, Zuzanna Kanduła, Grzegorz Helbig and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Systemic Mastocytosis Treatment with Midostaurin: [Diagnostics (Basel, Switzerland) · 2022
    Article
  6. Treatment of Indolent and Advanced Systemic Mastocytosis.Mediterranean journal of hematology and infectious diseases · 2022
    Review
  7. Precision Medicine in Systemic Mastocytosis.Medicina (Kaunas, Lithuania) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Aneta Szudy-SzczyrekChair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin Staszica Street 11, 20-081 Lublin, Poland.ORCID 0000-0003-2352-394X
Oliwia Bachanek-MituraChair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin Staszica Street 11, 20-081 Lublin, Poland.
Tomasz GromekChair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin Staszica Street 11, 20-081 Lublin, Poland.
Karolina ChromikDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia in Katowice, 40-032 Katowice, Poland.
Andrzej MitalDepartment of Hematology and Transplantology, Medical University of Gdańsk, 80-211 Gdańsk, Poland.
Michał SzczyrekChair and Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Witold KrupskiII Department of Medical Radiology, Medical University of Lublin, 20-081 Lublin, Poland.
Justyna SzumiłoChair and Department of Clinical Pathomorphology, Medical University of Lublin, 20-090 Lublin, Poland.
Zuzanna KandułaDepartment of Hematology and Bone Marrow Transplantation, University of Medical Sciences in Poznan, 61-001 Poznań, Poland.
Grzegorz HelbigDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia in Katowice, 40-032 Katowice, Poland.
Marek HusChair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin Staszica Street 11, 20-081 Lublin, Poland.
Medical University of Lublin · PLMedical University of Silesia · PLGdańsk Medical University · PLPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In April 2017 midostaurin was approved by the US Food and Drug Administration for the treatment of patients with aggressive systemic mastocytosis (ASM). So far, very limited real world data on its efficacy is available. Thirteen patients aged from 48 to 79 years, who received midostaurin in the early access program, were included in the study. Midostaurin was used both in first (

Indexed as

aggressive systemic mastocytosisKIT D816V mutationmast cellsmidostaurintryptase

Identifiers

PMID33799933
PMCPMC7961806
OpenAlexW3134904721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.